Advancing molecular medicine with new therapeutic compounds
Nature regulates biochemical signals using on/off switches, each of which is specific to a given biochemical signal. Allinky follows a similar approach to design molecular switches that act on biochemical signals known to drive cancer and inflammation. Allinky’s switches are small chemical compounds referred to as allosteric inhibitors thanks to the way in which they produce their effects. The design of each switch is unique and it requires several years of challenging R&D activity, both at the computational and chemical levels.
Allinky operates its proprietary technology platform in collaboration with top academic/clinical institutions around the globe, and in partnership with pharmaceutical companies.